
Wednesday, May 18, 2022 4:26:40 PM
Your post is simply speculation.
That was after I offered all the calculations and sources.
So if you are going to say something like that, prove it with facts, sources and calculations.
Now you are saying something different. That we don't know. But let's recapitulate, what I said is that all of the patients with KNOWN MGMT gene promoter methylation status in the group of these 35 patients that never crossed over are MGMT methylated and that of the patients with still unknown MGMT gene promoter methylation status, almost all if not all are MGMT Methylated.
This last part is the only one that you could have seen as speculation. But actually it wasn't. If you apply simple statistics, you have a group of 35 patients with the following distribution:
- Known MGMT 13
- Unknown MGMT 22
Out of the 13 with known MGMT methylation you have:
- Methylated 13 100%
- Non Methylated 0 0%
Do you know how big is this sample from a statistical point of view to infer something from it? Hard to find a sample as big as this 37% (13/35) in a survey. We know the information for 37% of the universe to make a statistical analysis and in that sample, 100% of them are Methylated.
Finally, I have always believed what you mention here:
What I think this shows is that most of the 24 unidentified mgmt amongst the non-crossovers probably came from early in the trial, before satisfactory mgmt methylation tests were developed. 2008
And actually I used that as a support in the statistical analysis I did, because this means that the selection of the population of patients with unknown MGMT is not biased towards unmethylated, nor methylated MGMT because the trial was randomized at the beginning and the MGMT Methylated and MGMT Unmethylated patients were assigned to both original arms in the statistically correct proportions.
So, I say that at least the majority of the 35 non crossed over patients are MGMT Methylated and this is not speculation, is a conclusion statistically inferred. Also, the rest of my post definitely was not speculation, was made up of facts, calculations and analyses.
Volume: | 2,199,435 |
Day Range: | 0.194 - 0.21 |
Bid: | 0.196 |
Ask: | 0.2018 |
Last Trade Time: | 3:11:20 PM EDT |
Total Trades: | 859 |
Recent NWBO News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
- Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments • AllPennyStocks.com • 01/13/2025 01:56:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/26/2024 10:07:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:29:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:10:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
FEATURED Nightfood Holdings (OTCQB: NGTF) Signs $41M LOI to Acquire Victorville Hotel as Model Property for Robotics-Enabled Hospitality • Apr 8, 2025 11:21 AM
VAYK Projects $680K 2024 Revenue with $310K Net Profit • VAYK • Apr 8, 2025 9:34 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for the Year Ended December 31, 2024 • HYDI • Apr 8, 2025 9:30 AM
Unlocking the Future of Hospitality with AI-Powered Robotics, Invaluable Industry Expertise • SYM • Apr 8, 2025 9:00 AM
UAV Corp and Genetic Networks Announce Strategic Collaboration to Combat Biohazards with Cutting-Edge Technology • UMAV • Apr 8, 2025 8:30 AM
Maybacks Global Entertainment Partners With LIME X To Bring Its iDreamCTV App To A Massive Audience • AHRO • Apr 8, 2025 8:30 AM